Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Dec 28, 2021; 27(48): 8357-8369
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8357
Table 1 Patient characteristics during first-line doublet chemotherapy according to treatment period
Clinical characteristicsTraining set (2012-2015), n = 937
Validation set (2008-2011), n = 946
P value
Sex, male, n (%)583 (62.2)637 (67.3)0.020
Age
Median, range56 (19-91)57 (20-85)0.785
≥ 65 yr, n (%)257 (27.4)259 (27.4)0.981
ECOG PS, n (%)
0/1799 (85.6)817 (86.6)0.531
2/3134 (14.4)126 (13.4)
Prior gastrectomy performed389 (41.5)412 (43.6)0.372
Histology, n (%)
WD/MD212 (22.6)256 (27.1)< 0.001
PD/SRC/undifferentiated691 (73.7)590 (62.4)
Unclassified34 (3.6)100 (10.6)
Status, n (%)
Recurrent318 (33.9)334 (35.3)0.533
Initial metastatic619 (66.1)612 (64.7)
Metastasis No., 2 or more385 (41.5)363 (38.9)0.249
Peritoneal metastasis518 (55.6)524 (55.9)0.902
Liver metastasis160 (17.2)226 (24.1)< 0.001
Lung metastasis45 (4.9)43 (4.6)0.795
PALN metastasis346 (37.3)352 (37.5)0.942
Bone metastasis93 (10.0)70 (7.5)0.051
ALP > 120 IU/L, n (%)201 (21.5)197 (21.2)0.868
Albumin < 3.3 g/dL, n (%)279 (29.8)249 (26.8)0.150
Total bilirubin > 1.2 mg/dL, n (%)62 (6.6)77 (8.3)0.177
NLR ≥ 3, n (%)381 (40.7)375 (40.3)0.881